Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
NDA, MAA Remain Key Focal Points for Celator Pharma (CPXX) Moving Forward; Roth Affirms at 'Buy'
March 21, 2016 11:31 AM EDTRoth Capital affirms Celator Pharmaceuticals (Nasdaq: CPXX) with a Buy rating and $22 price target after the company announced FY15 results earlier.
Analyst Joseph Pantginis noted that Celator posted FY15 EPS of ($0.57), which compares with the firm's ($0.56) estimate.
Pantginis also commented: With historic data in hand and a significantly de-risked program, in... More
Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c
March 21, 2016 8:21 AM EDTCelator Pharmaceuticals (NASDAQ: CPXX) reported Q4 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).
The following are expected milestones for VYXEOS:
3Q 2016 New Drug Application (NDA) submission1Q 2017 Marketing Authorization Application (MAA) submissionMid-2017 Prescription Drug User Fee Act (PDUFA)... More